National Bank of Canada FI Boosts Stock Position in Charles River Laboratories International, Inc. $CRL

National Bank of Canada FI lifted its stake in Charles River Laboratories International, Inc. (NYSE:CRL) by 1,179.5% in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 434,868 shares of the medical research company’s stock after purchasing an additional 400,881 shares during the quarter. National Bank of Canada FI owned about 0.88% of Charles River Laboratories International worth $65,983,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Nuveen LLC purchased a new position in shares of Charles River Laboratories International during the 1st quarter worth $18,538,000. Public Sector Pension Investment Board grew its holdings in shares of Charles River Laboratories International by 113.7% in the first quarter. Public Sector Pension Investment Board now owns 13,659 shares of the medical research company’s stock valued at $2,056,000 after purchasing an additional 7,266 shares during the period. Dimensional Fund Advisors LP increased its position in Charles River Laboratories International by 30.0% during the first quarter. Dimensional Fund Advisors LP now owns 862,254 shares of the medical research company’s stock worth $129,799,000 after purchasing an additional 198,750 shares during the last quarter. Ethic Inc. purchased a new position in Charles River Laboratories International during the first quarter worth about $523,000. Finally, American Century Companies Inc. boosted its holdings in Charles River Laboratories International by 29.1% in the 1st quarter. American Century Companies Inc. now owns 3,853 shares of the medical research company’s stock valued at $580,000 after purchasing an additional 869 shares during the last quarter. Institutional investors and hedge funds own 98.91% of the company’s stock.

Charles River Laboratories International Stock Down 0.8%

NYSE:CRL opened at $192.95 on Monday. Charles River Laboratories International, Inc. has a 52 week low of $91.86 and a 52 week high of $199.66. The stock’s fifty day moving average is $177.40 and its two-hundred day moving average is $163.66. The stock has a market capitalization of $9.50 billion, a price-to-earnings ratio of -123.68, a price-to-earnings-growth ratio of 6.82 and a beta of 1.63. The company has a quick ratio of 1.10, a current ratio of 1.37 and a debt-to-equity ratio of 0.64.

Charles River Laboratories International (NYSE:CRL) last posted its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.32 by $0.11. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.78% and a negative net margin of 2.07%.Charles River Laboratories International’s revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.59 EPS. Research analysts anticipate that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Analysts Set New Price Targets

A number of analysts have recently issued reports on CRL shares. TD Cowen cut their price target on shares of Charles River Laboratories International from $205.00 to $197.00 and set a “buy” rating for the company in a report on Monday, November 10th. Weiss Ratings reiterated a “sell (d)” rating on shares of Charles River Laboratories International in a report on Wednesday, October 8th. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and raised their target price for the stock from $178.00 to $199.00 in a research note on Thursday, November 6th. Barclays lifted their target price on Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. Finally, Jefferies Financial Group raised Charles River Laboratories International from a “hold” rating to a “buy” rating and upped their price target for the company from $142.00 to $195.00 in a research note on Tuesday, September 9th. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of “Moderate Buy” and a consensus price target of $189.38.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).